ANW.F Immuron Limited

Healthcare Biotechnology Frankfurt Exchange
0.0125 EUR
Close of Nov 12, 2026
0.0060 0.0365
Market cap
EUR 4.04M
P/E
-
P/B
0.74x
ROE
-33.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Jun 2026.

Is ANW.F undervalued?

Graham number

The Graham number of Immuron Limited cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Immuron Limited fundamental analysis

No fundamental analysis for Immuron Limited yet.

Immuron Limited stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Immuron Limited

Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as …

Full company profile